IRB #

STUDY00017285

Title

A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non infectious Uveitis

Principal Investigator

Eric Suhler

Study Purpose

To evaluate the safety and efficacy of filgotinib vs. placebo for the treatment of the signs and symptoms of non-infectious uveitis.

Medical Condition(s)

non-infectious uveitis

Eligibility Criteria

Adult subjects 18 years or older with active, non-infectious
intermediate-, posterior-, or pan-uveitis

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Subjects will receive a maximum of 52 weeks of study drug in the
randomized, double-masked trial

Minors Included

No

Contact

Tracy Giles
503-494-0482
gilest@ohsu.edu

Sponsor

Gilead Sciences, Inc.

Recruitment End

12/31/2018

Compensation Provided

Yes

Compensation

$50 per visit


Go Back